Link to the University of Pittsburgh Homepage
Link to the University Library System Homepage Link to the Contact Us Form
D-Scholarship @ Pitt Banner and Links to Homepage

Alemtuzumab pre-conditioning with tacrolimus monotherapy in pediatric renal transplantation

Shapiro, R and Ellis, D and Tan, HP and Moritz, ML and Basu, A and Vats, AN and Kayler, LK and Erkan, E and McFeaters, CG and James, G and Grosso, MJ and Zeevi, A and Gray, EA and Marcos, A and Starzl, TE (2007) Alemtuzumab pre-conditioning with tacrolimus monotherapy in pediatric renal transplantation. American Journal of Transplantation, 7 (12). 2736 - 2738. ISSN 1600-6135

[img]
Preview
 PDF
Accepted Version
Available under License : See the attached license file.
Download (533kB) | Preview
[img] Plain Text (licence)
Available under License : See the attached license file.
Download (1kB)

Abstract

We employed antibody pre-conditioning with alemtuzumab and posttransplant immunosuppression with low-dose tacrolimus monotherapy in 26 consecutive pediatric kidney transplant recipients between January 2004 and December 2005. Mean recipient age was 10.7 ± 5.8 years, 7.7% were undergoing retransplantation, and 3.8% were sensitized, with a PRA >20%. Mean donor age was 32.8 ± 9.2 years. Living donors were utilized in 65% of the transplants. Mean cold ischemia time was 27.6 ± 6.4 h. The mean number of HLA mismatches was 3.3 ± 1.3. Mean follow-up was 25 ± 8 months. One and 2 year patient survival was 100% and 96%. One and 2 year graft survival was 96% and 88%. Mean serum creatinine was 1.1 ± 0.6 mg/dL, and calculated creatinine clearance was 82.3 ± 29.4 mL/min/1.73 m 2. The incidence of pre-weaning acute rejection was 11.5%; the incidence of delayed graft function was 7.7%. Eighteen (69%) of the children were tapered to spaced tacrolimus monotherapy, 10.5 ± 2.2 months after transplantation. The incidence of CMV, PTLD and BK virus was 0%; the incidence of posttransplant diabetes was 7.7%. Although more follow-up is clearly needed, antibody pre-conditioning with alemtuzumab and tacrolimus monotherapy may be a safe and effective regimen in pediatric renal transplantation. © 2007 The Authors.

Share

Citation/Export:
Social Networking:
Share |

Details

Item Type: Article
Status: Published
Creators/Authors:
CreatorsEmailPitt UsernameORCID
Shapiro, R
Ellis, D
Tan, HP
Moritz, ML
Basu, A
Vats, AN
Kayler, LK
Erkan, E
McFeaters, CG
James, G
Grosso, MJ
Zeevi, A
Gray, EA
Marcos, A
Starzl, TEtes11@pitt.eduTES11
Centers: Other Centers, Institutes, Offices, or Units > Thomas E. Starzl Transplantation Institute
Date: 1 December 2007
Date Type: Publication
Journal or Publication Title: American Journal of Transplantation
Volume: 7
Number: 12
Page Range: 2736 - 2738
DOI or Unique Handle: 10.1111/j.1600-6143.2007.01987.x
Institution: University of Pittsburgh
Refereed: Yes
ISSN: 1600-6135
Other ID: uls-drl:31735062121383, Starzl CV No. 2230
Date Deposited: 08 Apr 2010 17:38
Last Modified: 22 Jun 2021 14:56
URI: http://d-scholarship.pitt.edu/id/eprint/5616

Metrics

Monthly Views for the past 3 years

Plum Analytics

Altmetric.com

Actions (login required)

View Item View Item